恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究*

doi:10.3969/j.issn.1672-5069.2024.05.009

摘要/Abstract

摘要： 目的分析恩替卡韦(ETV)经治慢性乙型肝炎(CHB)患者发生低病毒血症(LLV)的危险因素及转换富马酸丙酚替诺福韦(TAF)治疗的疗效。方法 2020年1月～2022年12月我院收治的ETV经治的CHB患者158例,对获得完全病毒学应答(CVR)者继续口服ETV,对发生LLV者则转换为TAF治疗,两组均观察48 w。使用超敏PCR检测系统检测血清HBV DNA,使用全自动化学发光免疫分析仪检测血清HBeAg和HBsAg定量。应用Logistic回归分析影响ETV经治CHB患者发生LLV的危险因素。结果在纳入的经ETV治疗至少48 w的158例CHB患者中,发现LLV者55例(34.8%)和CVR者103例(65.2%);单因素分析发现体质指数、乙型肝炎家族史、合并代偿期肝硬化、基线HBV DNA载量、血清HBeAg阳性和血清HBsAg水平与ETV治疗发生LLV相关(P＜0.05),多因素Logistic回归分析显示,基线血清HBV DNA高载量(OR:2.793,95%CI:1.579～4.940)、HBeAg阳性(OR:2.337,95%CI:1.455～3.756)和血清HBsAg高水平(OR:1.931,95%CI:1.338～2.786)是ETV治疗CHB患者发生LLV的独立危险因素(P＜0.05);在TAF转换治疗48 w末,55例LLV患者获得CVR者36例(65.5%);LLV组血清ALT水平、HBV DNA载量和HBsAg定量仍显著高于CVR组【分别为37.2(19.1,57.0)U/L、(0.9±0.4)lg IU/ml和(3.9±0.6)lg IU/ml对33.5(17.6,39.2)U/L、(0.7±0.3)lg IU/ml和(3.1±0.5)lg IU/ml,P＜0.05】。结论恩替卡韦治疗CHB患者基线血清HBV DNA高载量、HBeAg阳性和血清HBsAg定量水平高是发生LLV的危险因素,而大部分LLV患者转换TAF治疗可获得较好的病毒学应答率,值得进一步研究。

关键词: 慢性乙型肝炎, 低病毒血症, 恩替卡韦, 富马酸丙酚替诺福韦, 危险因素, 转换治疗

Abstract: Objective The aim of this study was to investigate the risk factors of low-level viremia (LLV) and rescue switch treatment to tenofovir alafenamide fumarate (TAF) in entecavir(ETV)-treated patients with chronic hepatitis B(CHB). Methods A total of 158 patients with CHB were enrolled in our hospital between January 2020 and December 2022, and all were already had treated with ETV for at least 48 weeks. The patients who obtained complete virological response (CVR) continued the ETV treatment, and those with LLV were switched to TAF treatment. The patients in the two groups were observed for 48 weeks. Serum HBV DNA loads were detected by hypersensitive PCR detection system, serum HBeAg and HBsAg quantification were detected by full-automatic chemiluminescence immunoanalyzer. The risk factors of LLV in CHB patients undergoing ETV treatment were analyzed by multivariate Logistic regression analysis. Results Out of the 158 patients with CHB enrolled in this study, the LLV was found in 55 cases(34.8%)and the CVR in 103 cases (65.2%); the body mass index, family hepatitis B history, concomitant liver cirrhosis, baseline serum HBV DNA loads, serum HBeAg positive and serum HBsAg levels were correlated to the occurrence of LLV(P＜0.05), and the multivariate Logistic regression analysis showed that the baseline serum HBV DNA loads (OR:2.793, 95%CI:1.579-4.940), serum HBeAg positive (OR:2.337,95%CI:1.455-3.756) and serum HBsAg high levels (OR:1.931, 95%CI:1.338-2.786) were the independent risk factors for LLV occurrence in ETV-treated patients with CHB (P＜0.05); at the end of 48-week of TAF treatment, the CVR was obtained in 36 cases (65.5%) in 55 patients with LLV, and serum ALT level, HBV DNA load and HBsAg level in 55 patients with LLV were still significantly higher than those with CVR [37.2(19.1,57.0)U/L, (0.9±0.4)lg IU/ml and (3.9±0.6)lg IU/ml vs. 33.5(17.6, 39.2)U/L, (0.7±0.3)lg IU/ml and (3.1±0.5)lg IU/ml, respectively, P＜0.05]. Conclusion The high baseline serum HBV DNA loads, HBeAg positive and high HBsAg quantification might be the risk factors for LLV occurrence in ETV-treated patients with CHB and the rescue TAF treatment could get CVR in most of them, which warrants further clinical investigation.

Key words: Hepatitis B, Low-level viremia, Entecavir, Tenofovir alafenamide fumarate, Risk factor, Rescue treatment

冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.

Ran Shurong, Liu Yang, Lei Lan. Risk factors of low-level viremia and rescue switch treatment to tenofovir alafenamide fumarate in entecavir-treated patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2024, 27(5): 681-684.

参考文献

[1] Liao MJ, Li J, Dang W, et al. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China. World J Gastroenterol, 2022, 28(27):3503-3513.
[2] Johnson Valiente A, Liem KS, Schwarz KB, et al. The inflammatory cytokine profile associated with Liver damage is broader and stronger in patients with chronic hepatitis B compared to patients with acute hepatitis B. J Infect Dis, 2022, 225(3):470-475.
[3] Kamal F, Khan MA, Ahmed A, et al. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B. Gut, 2020,69(11):2054-2056.
[4] Shen J, Qi W, Dai J, et al. Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy. Chin Med J (Engl), 2021, 135(3):301-308.
[5] Hagiwara S, Nishida N, Ueshima K, et al. Comparison of efficacy and safety of entecavir and switching from entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: long-term effects from a prospective study. Hepatol Res, 2021, 51(7):767-774.
[6] Li ZB, Li L, Niu XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021, 41(6):1254-1264.
[7] 符鑫, 刘悦, 彭鑫, 等. 采用高敏检测技术检测血清HBV DNA载量筛选低病毒血症的无偿献血人群隐匿性乙型肝炎病毒感染研究. 实用肝脏病杂志, 2023, 26(2):169-172.
[8] Huang DQ, Tamaki N, Lee HW, et al. Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV DNA in compensated cirrhosis. Hepatology, 2023, 77(5):1746-1756.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[10] Surial B, Wyser D, Béguelin C, et al. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: systematic review and meta-analysis. Liver Int, 2021, 41(4):710-719.
[11] Gao X, Yang HI, Trinh H, et al. Antiviral therapy and hepatocellular carcinoma risk in hepatitis B patients with cirrhosis. Eur J Gastroenterol Hepatol, 2020, 32(9):1207-1211.
[12] Chon HY, Ahn SH, Kim YJ, et al. Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hepatol Int, 2021, 15(6):1328-1336.
[13] Peng D, Xing HY, Li C, et al. The clinical efficacy and adverse effects of entecavir plus thymosin alpha-1 combination therapy versus entecavir monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol, 2020, 20(1):348.
[14] Kim JH, Sinn DH. Low-level viremia in patients undergoing antiviral therapy: Does it indicate time for a change? Clin Mol Hepatol, 2020, 26(3):315-317.
[15] 李彤, 孔银, 刘元元, 等. 经治慢性乙型肝炎低病毒血症患者人群特征及其相关影响因素:一项单中心横断面回顾性研究. 中华肝脏病杂志, 2023, 31(1):42-48.
[16] Lee SB, Jeong J, Park JH, et al. Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. Clin Mol Hepatol, 2020, 26(3):364-375.
[17] Yin GQ, Li J, Zhong B, et al. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. World J Gastroenterol, 2021, 27(8):666-676.
[18] Zhang Q, Peng H, Liu X, et al. Chronic hepatitis B infection with low level viremia correlates with the progression of the liver disease. J Clin Transl Hepatol, 2021, 9(6):850-859.
[19] Han J, Guo Y, Zhang X, et al. Prevalence and associated factors of low-level viremia in chronic hepatitis B patients after long-term therapy with nucleos(t)ide analogs. Turk J Gastroenterol, 2023, 34(1):53-61.
[20] Kim JH, Sinn DH, Kang W, et al. Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology, 2017, 66(2):335-343.
[21] Meier MA, Calabrese D, Suslov A, et al. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol, 2021, 75(4):840-847.
[22] Durantel D, Dousson CB, Lampertico P. Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? J Hepatol, 2021, 74(5):1011-1014.
[23] Kanda N, Okamoto K, Okumura H, et al. Outcomes associated with treatment change from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-1-infected patients: a real-world study in Japan. HIV Med, 2021, 22(6):457-466.
[24] Pilkington V, Hughes SL, Pepperrell T, et al. Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials. AIDS, 2020,34(15):2259-2268.
[25] Lim J, Choi WM, Shim JH, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B. Liver Int, 2022, 42(7):1517-1527.

恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*

Risk factors of low-level viremia and rescue switch treatment to tenofovir alafenamide fumarate in entecavir-treated patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[2]	李双玲, 刘丽, 陈艺, 李坤. 富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 749-752.
[3]	连作勤, 王世明, 张甲, 李付平. 富马酸丙酚替诺福韦联合复方鳖甲软肝片治疗乙型肝炎肝硬化患者疗效和安全性评估^*[J]. 实用肝脏病杂志, 2024, 27(5): 753-756.
[4]	张怀东, 雷宇, 周智. 失代偿期肝硬化合并肝外脓肿患者临床特点分析[J]. 实用肝脏病杂志, 2024, 27(5): 761-764.
[5]	廖敏君, 饶慧瑛. 脂肪性肝病相关肝细胞癌筛查和监测策略[J]. 实用肝脏病杂志, 2024, 27(4): 484-487.
[6]	张全乐, 赵丹, 李杰, 刘三香, 刘刚, 李亚. 富马酸替诺福韦与恩替卡韦挽救治疗拉米夫定耐药的HBeAg阴性慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 515-518.
[7]	薛李娜, 诸国兵, 吴琳霖, 杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 519-522.
[8]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[9]	李勇, 张蕾, 吴幸福. 老年药物性肝损伤患者临床特征分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 547-550.
[10]	虞珊珊, 张业婷, 王元鹏, 袁静文, 肖立. 慢性乙型肝炎患者血清MMP-1、MMP-2、TIMP-1和HIF-1α变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(3): 329-332.
[11]	罗良德, 任成果, 王守军, 邓颖春. 恩替卡韦联合多烯磷脂酰胆碱治疗慢性乙型肝炎合并NASH患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 333-336.
[12]	周安琪, 孟舒婷, 吴应冬, 张弦. 接受核苷(酸)类似物抗病毒的慢性乙型肝炎患者发生低病毒血症危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 337-340.
[13]	尹丹丹, 张瑞珏, 王帅, 代爱军, 周正, 张帆. 30岁以下血清ALT正常的成人慢性HBV感染者肝组织学变化研究[J]. 实用肝脏病杂志, 2024, 27(3): 341-344.
[14]	彭玉静, 郭航, 陈俊光. 应用超声评分联合STE/STQ定量检测肝脏硬度评估慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(3): 345-348.
[15]	农晓黎, 陈菲, 詹浩洪, 罗婷, 曾碧丹. 体检人群非酒精性脂肪性肝病发病率及其相关危险因素分析^*[J]. 实用肝脏病杂志, 2024, 27(3): 353-356.